

Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

[Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic](#)

Mar 27 2020, 6:19 PM EDT

[Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa](#)

Mar 17 2020, 7:30 AM EDT

[Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates](#)

Mar 16 2020, 4:20 PM EDT

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	198.18m
Last Price	\$2.37
52-Week	\$1.35 - \$8.41

04/08/2020 04:00 PM EDT

Investor Relations

ir@abeonatherapeutics.com

Management Team

João Siffert, M.D.

Chief Executive Officer, Head of Research & Development and Chief Medical Officer

Jay Bircher

Chief Technical Officer

Edward Carr

Chief Accounting Officer

Victor Paulus, Ph.D.

Senior Vice President, Head of Regulatory Affairs

Juan Ruiz, M.D., Ph.D.

Head of European Medical Affairs

Jodie Gillon, M.P.H.

Vice President, Patient Advocacy & Clinical Affairs

Brendan O'Malley, J.D., Ph.D.

Vice President, Head of Legal and IP

Kristina Maximenko

Vice President, Human Resources

Scott Nogi

Vice President, Business Operations

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.